tl;dr of above notification
- ImmunoACT has received marketing authorization for their groundbreaking CD19-targeted CAR-T cell therapy product, NexCAR19 in India
- The cell therapy product is indigenously made in India, cost-effective, and designed to treat blood cancer (relapsed/refractory B-cell lymphomas and leukemia) and it puts India in the list of select elites who have such a solution
- Laurus Labs is an early supporter of ImmunoACT with an investment of over USD 18 million
- ImmunoACT intends to make NexCAR19 therapy available to its partner hospitals soon
| Subscribe To Our Free Newsletter |
